Press Releases | PTC Therapeutics, Inc.

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date	Title and Summary	View
Oct 26, 2010	PTC Therapeutics Initiates Phase 2 Clinical Trial of Ataluren in Patients with Methylmalonic Acidemia - First proof-of-concept clinical study of ataluren in a metabolic disorder -
Oct 15, 2010	PIVOTAL DATA PRESENTED AT THE WORLD MUSCLE SOCIETY CONGRESS SUGGEST ATALUREN SLOWS THE LOSS OF WALKING ABILITY IN PATIENTS WITH NONSENSE MUTATION DUCHENNE/BECKER MUSCULAR DYSTROPHY - 29.7 meter average change in 6-minute walk distance compared to placebo at 48 weeks - - Safety results show ataluren was generally well tolerated - - Data to be the basis of interactions with regulatory authorities -
Sep 21, 2010	PTC THERAPEUTICS AWARDED $1.6 MILLION FDA ORPHAN DRUG GRANT TO SUPPORT AN ONGOING PHASE 3 STUDY IN CYSTIC FIBROSIS SOUTH PLAINFIELD, NJ – SEPTEMBER 21, 2010 – PTC Therapeutics, Inc. (PTC) today announced a grant award of approximately $1.6 million from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OPD) to support an ongoing Phase 3 study of ataluren in patients with nonsense
Jun 07, 2010	PTC THERAPEUTICS AWARDED $5.4 MILLION GRANT FROM THE WELLCOME TRUST -Over $100 Million in Cumulative Grant Funding Raised to Date-
Mar 03, 2010	PTC THERAPEUTICS AND GENZYME CORPORATION ANNOUNCE PRELIMINARY RESULTS FROM THE PHASE 2B CLINICAL TRIAL OF ATALUREN FOR NONSENSE MUTATION DUCHENNE/BECKER MUSCULAR DYSTROPHY SOUTH PLAINFIELD, NJ and CAMBRIDGE, MA – March 03, 2010 – PTC Therapeutics, Inc. and Genzyme Corporation (Nasdaq: GENZ) today announced preliminary results from the Phase 2b clinical trial of ataluren, an investigational new drug, in patients with nonsense mutation Duchenne/Becker Muscular
Jan 19, 2010	PTC THERAPEUTICS ANNOUNCES ADDITIONAL STUDY OF ATALUREN IN PATIENTS WITH ADVANCED NONSENSE MUTATION DUCHENNE/BECKER MUSCULAR DYSTROPHY - Study funded in part by a grant from the Muscular Dystrophy Association-